- All categories
- Electronics, IT and Telecomms
- Industrial manufacturing, Material and Transport Technologies
- Industrial Technologies
- Energy Technology
- Physical Sciences and Exact Sciences
- Biological Sciences
- Agriculture and Marine Resources
- Agrofood Industry
- Measurements and Standards
- Protecting Man and Environment
- Social and Economics concerns
- Medical Health related
- Diagnostic
- Diagnostic services
- Therapeutic
- Other Medical/Health Related
- Agro and Marine biotech
- Anatomy, Pathology, Immunology, Physiology
- Clinical Medicine
- Medical equipment
- Welfare technologies
- Plant and animal health
- Covid-19
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this Technology Call
Seeking Proposals for Projects in the Development, Piloting and Demonstration stages to cope with the CoronavirusThe Israel Innovation Authority, in cooperation with the Ministry of Health and the Headquarters for the National Digital Israel Initiative are issuing a Call for Proposals to Israeli technology companies (that are not one of Israel's health organizations) to submit R&D plans for systems, products, or technological solutions, including projects in the development, piloting and demonstration stages (as well as semi-commercial installation and implementation. and large-scale deployment in heath organizations) designed to deal with the challenges posed by the COVID-19 (coronavirus) pandemic. Relevant Technologies: All relevant technologies
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this Technology Call
Seeking candidates to apply to the LifeArc COVID-19 FundLifeArc has made available an initial £10M for the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. It is anticipated that applications will be for funding to repurpose one or more drugs that are generic, already licensed, or are in late stage development for another indication.
